Correlation
The correlation between APLS and VRTX is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
APLS vs. VRTX
Compare and contrast key facts about Apellis Pharmaceuticals, Inc. (APLS) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: APLS or VRTX.
Performance
APLS vs. VRTX - Performance Comparison
Loading data...
Key characteristics
APLS:
-1.09
VRTX:
-0.01
APLS:
-1.75
VRTX:
0.14
APLS:
0.79
VRTX:
1.02
APLS:
-0.71
VRTX:
-0.05
APLS:
-1.72
VRTX:
-0.11
APLS:
33.78%
VRTX:
9.51%
APLS:
53.78%
VRTX:
28.65%
APLS:
-82.47%
VRTX:
-91.77%
APLS:
-81.86%
VRTX:
-14.45%
Fundamentals
APLS:
$2.13B
VRTX:
$114.81B
APLS:
-$1.80
VRTX:
-$3.76
APLS:
2.74
VRTX:
10.34
APLS:
12.96
VRTX:
6.96
APLS:
$775.84M
VRTX:
$11.10B
APLS:
$643.52M
VRTX:
$9.55B
APLS:
-$176.07M
VRTX:
-$76.30M
Returns By Period
In the year-to-date period, APLS achieves a -46.94% return, which is significantly lower than VRTX's 9.77% return.
APLS
-46.94%
-15.69%
-50.10%
-56.87%
-25.80%
-12.86%
N/A
VRTX
9.77%
-11.39%
-5.57%
-2.92%
18.06%
8.95%
13.48%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
APLS vs. VRTX — Risk-Adjusted Performance Rank
APLS
VRTX
APLS vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
APLS vs. VRTX - Dividend Comparison
Neither APLS nor VRTX has paid dividends to shareholders.
Drawdowns
APLS vs. VRTX - Drawdown Comparison
The maximum APLS drawdown since its inception was -82.47%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for APLS and VRTX.
Loading data...
Volatility
APLS vs. VRTX - Volatility Comparison
Apellis Pharmaceuticals, Inc. (APLS) has a higher volatility of 15.97% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 13.31%. This indicates that APLS's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
APLS vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
APLS vs. VRTX - Profitability Comparison
APLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Apellis Pharmaceuticals, Inc. reported a gross profit of 132.44M and revenue of 166.80M. Therefore, the gross margin over that period was 79.4%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.
APLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Apellis Pharmaceuticals, Inc. reported an operating income of -83.33M and revenue of 166.80M, resulting in an operating margin of -50.0%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.
APLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Apellis Pharmaceuticals, Inc. reported a net income of -92.23M and revenue of 166.80M, resulting in a net margin of -55.3%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.